This product is for the diagnosis of cancer, not respiratory...

This product is for the diagnosis of cancer, not respiratory illness. Cancer is not something you want to misdiagnose and the accuracy hurdle must be very high indeed. Respiratory illness has a relatively high rate of misdiagnosis and is not commonly fatal. Hurdle is therefore lower, and I would expect that an 86% accuracy result in the ResApp study would be more than sufficient to achieve FDA approval for clinical use. Btw, the company met with the FDA in March last year, there is no new information here.